Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

TAKEDA PHARMACEUTICAL CO LTD (4502)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Takeda Pharmaceutical : eyes selling Osaka headquarters to fund Shire purchase

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/05/2018 | 11:23pm EST

Takeda Pharmaceutical Co. is considering selling its symbolic Osaka headquarters building to help finance the 46 billion pound ($60 billion) deal to acquire Irish drugmaker Shire Plc., sources close to the matter said Friday.

The building, located in Dosho in the city of Osaka, western Japan, stands on the same site where the company was founded in 1781. While Takeda has moved its headquarter functions to its Tokyo office, the building in Dosho, historically known as a town of medicine, is registered as its official headquarters.

Takeda is expected to raise tens of billions of yen through the sale of the building, in an effort to bolster its finances and quell criticism by some of its shareholders that the Shire deal is too costly.

The purchase of London-listed Shire amounts to the biggest-ever Japanese acquisition of a foreign company.

Takeda is aiming to win shareholder approval in early 2019 for an issue of new shares to finance the acquisition, and close the deal by next June.

Among other efforts to streamline its businesses, Takeda sold last year its roughly 70 percent stake in its chemical research unit Wako Pure Chemical Industries Ltd. to Fujifilm Holdings Corp. for around 155 billion yen.

It has also decided to sell properties, including a former Tokyo headquarters building in the capital's Chuo Ward, to department store operator Takashimaya Co. for around 50 billion yen.

==Kyodo

© Kyodo News International, Inc., source Newswire

Stocks mentioned in the article
ChangeLast1st jan.
SHIRE 2.42% 4690 Delayed Quote.0.00%
TAKEDA PHARMACEUTICAL CO LTD -1.37% 4388 End-of-day quote.21.22%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL CO L
01/22TAKEDA PHARMACEUTICAL : Recognized as a Global 100 Most Sustainable Corporation ..
PU
01/21ASIA MARKETS: Asian Markets Rise Despite Slower Economic Growth In China
DJ
01/19TAKEDA PHARMACEUTICAL : organises the first Hodgkin lymphoma regional summit  
AQ
01/19TAKEDA PHARMACEUTICAL : Lonza, Takeda reach regulatory milestone in oncology tie..
AQ
01/18TAKEDA PHARMACEUTICAL : Japanese Olympic Committee head Tsunekazu Takeda denies ..
AQ
01/18TAKEDA PHARMACEUTICAL : Japanese Olympic Committee head Tsunekazu Takeda denies ..
AQ
01/17TAKEDA PHARMACEUTICAL : Egypts Takeda Pharmaceutical to hold 1st Hodgkin lymphom..
AQ
01/16TAKEDA PHARMACEUTICAL : organises first Hodgkin lymphoma regional summit in pres..
AQ
01/16TAKEDA PHARMACEUTICAL : Korea names Moon Hee-seok as new CEO
AQ
01/14TAKEDA PHARMACEUTICAL : Lonza Collaborates with Takeda to Bring Cancer Treatment..
AQ
More news
Financials (JPY)
Sales 2019 2 432 B
EBIT 2019 -
Net income 2019 230 B
Debt 2019 5 755 B
Yield 2019 4,05%
P/E ratio 2019 30,32
P/E ratio 2020
EV / Sales 2019 5,23x
EV / Sales 2020 3,49x
Capitalization 6 963 B
Chart TAKEDA PHARMACEUTICAL CO LTD
Duration : Period :
Takeda Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 6 052  JPY
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD21.22%63 465
JOHNSON & JOHNSON-0.19%345 439
PFIZER-3.16%245 166
NOVARTIS4.88%225 489
ROCHE HOLDING LTD.5.59%221 685
MERCK AND COMPANY-0.76%197 187